Medicine is entering a new era - one where care is no longer based on averages, but on the unique biology of every individual.
The American Board of Precision Medicine (ABOPM) was founded to accelerate this transformation. As a nonprofit organization, ABOPM is dedicated to advancing the clinical application of precision medicine and preparing physicians for the next generation of healthcare.
Through education, certification, collaboration, and leadership development, ABOPM is building a global community of physicians committed to delivering personalized, data-driven medicine that improves patient outcomes and transforms healthcare systems.
We envision a world where healthcare is predictive, preventive, personalized, and participatory. Precision medicine transforms care from reactive treatment to proactive, data-driven intervention.
Integrating genomics and systems biology enables earlier detection and more targeted treatments.
AI and advanced diagnostics shift healthcare from reactive care to predictive prevention.
ABOPM empowers physicians to lead the future of personalized, precision-based healthcare.
The ABOPM Precision Oncology Department trains physicians to integrate tumor genomics, liquid biopsy, immunoprofiling, and targeted therapeutics into individualized treatment strategies — moving beyond population averages to treat each cancer as the unique disease it is.
Visit Department PagePrecision Oncology sits at the core of ABOPM's mission because cancer is the clearest proof case for precision medicine itself: every tumor carries a distinct genomic signature, and treating it as generic disease rather than individual biology costs patients time, response, and survival.
By establishing a board-certified standard for interpreting tumor genomics, monitoring treatment response, and matching patients to targeted and immune therapies, ABOPM gives physicians a credentialed framework the field currently lacks — and positions the organization at the forefront of where oncology is headed.
Sets the Clinical Standard
Establishes a rigorous, board-certified benchmark for genomic-driven cancer care where none currently exists.
Anchors a $560B Field
Prepares physicians for the fastest-growing segment of precision medicine, where genomic-guided treatment is now standard of care.
Strengthens ABOPM's Credibility
Demonstrates the depth of ABOPM's multidisciplinary faculty and reinforces its standing with partners, grantors, and academic collaborators.
Comprehensive Genomic Profiling
Somatic mutation analysis, copy number alterations, gene fusions, and mutational signatures across all tumor types.
Liquid Biopsy & ctDNA Monitoring
Real-time treatment response monitoring, minimal residual disease detection, and early resistance identification.
Immune Microenvironment Analysis
TMB, MSI status, PD-L1 expression, and TIL infiltration to identify immunotherapy responders.
Resistance Mechanism Mapping
Identifying acquired resistance pathways and adapting therapeutic strategy before clinical progression.
Identify actionable somatic mutations, copy number alterations, and gene fusions across every tumor site.
Guide institutional precision cancer programs and complex genomic treatment decisions.
Use ctDNA analysis to detect minimal residual disease and adapt therapy in real time.
Identify which patients respond to checkpoint inhibitors vs. combination or alternative immune strategies.
Every tumor has a molecular story.
Are you trained to read it?
The mission of the American Board of Precision Medicine is to accelerate the clinical adoption of precision medicine and improve global health outcomes.
Together, these initiatives help bridge the gap between scientific innovation and patient care.
ABOPM is committed to advancing the field of precision medicine through five key objectives—strengthening physician education, reducing chronic disease burden, translating research into clinical practice, building a global network of innovators, and advocating for the future of medicine.
Explore ABOPM perspectives on genomics, multi-omics, systems thinking, clinical innovation, and the future of physician leadership in precision medicine.
Discover how targeted therapies are transforming precision oncology by matching cancer treatments to genetic mutations, enabling more personalized and effective care. ...more
On the Frontier
July 15, 2026•9 min read
Discover how genomics, biomarkers, and precision cardiology help identify cardiovascular risk early and enable personalized prevention. ...more
Precision Medicine in Action
July 08, 2026•8 min read
Learn how targeted therapies match drugs to cancer-driving mutations, advancing precision oncology and improving treatment outcomes. ...more
Precision Oncology
July 01, 2026•9 min read
Subscribe to receive ABOPM insights, research updates, and educational resources delivered directly to your inbox.
© 2023-2025 American Board of Precision Medicine, Inc. All Rights Reserved.
